News | February 17, 2008

Exclusive Advanced Proton Therapy Training Facility to Open

February 18, 2008 –ProCure Treatment Centers Inc. and the University of Pennsylvania’s Roberts Proton Therapy Center have an agreement to provide advanced training programs and accredit medical professionals in proton therapy, an alternative to conventional radiation therapy that avoids many of the side effects inherent in treatment.

The agreement focuses on expanding research on the technology to be used for the delivery of proton therapy and developing new protocols using protons to treat a wider range of cancer tumors.

Protons are currently used primarily to treat about a dozen diagnoses including base-of-skull tumors, ocular melanoma, sinus tumors, pediatric cancers and prostate cancer. As more centers are developed and the capacity for patients increases, the Roberts Proton Therapy Center and ProCure have agreed to establish new clinical studies to evaluate the use of protons in areas such as proton therapy in combination with chemotherapy and the improved results obtained from increasing the dose delivered to the tumor. ProCure’s network of proton therapy centers will significantly increase the number of patients that can potentially be enrolled in studies, according to the company. The Center will provide oversight, establish data collection procedures, analyze data and work through any necessary regulatory process.

It is anticipated that within the next five years, at least 10 new proton therapy facilities will open in the U.S., including the Roberts Proton Therapy Center and several centers under development by ProCure, resulting in a need for trained staff at all levels. The Center and ProCure intend to collaborate on setting standards for proton therapy education and training, and will offer accreditation in the field. Training programs are slated to be provided at the ProCure Training and Development Center (TDC), a training center dedicated exclusively to proton therapy. The 20,000-square-foot training facility is located in Bloomington, IN. The TDC simulates a working proton therapy center and will provide training for radiation oncologists, medical physicists, dosimetrists, radiation therapists and other staff.

For more information: www.procurenews.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more